Caris Life Sciences said the company has been selected by the Hoosier Cancer Research Network and the study’s sponsor investigator, Matthew Galsky, to perform genomic tumor profiling for a new phase II bladder cancer clinical trial, HCRN GU16-257. This marks the second tumor profiling study Caris has been selected to lead within the Hoosier Cancer Research Network.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
